Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 Next >
Genmab Announces Financial Results for the First Nine Months of 2024
From Genmab A/S
Via GlobeNewswire
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Half of 2024
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2024 Financial Guidance
From Genmab A/S
Via GlobeNewswire
Genmab Takes Full Control of Acasunlimab Development Program
From Genmab A/S
Via GlobeNewswire
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Tickers GMAB
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Tickers BNTX GMAB
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via GlobeNewswire
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Quarter of 2024
From Genmab A/S
Via GlobeNewswire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via GlobeNewswire
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via GlobeNewswire
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Initiation of Share Buy-Back Program
From Genmab A/S
Via GlobeNewswire
Genmab Publishes 2023 Annual Report
From Genmab A/S
Via GlobeNewswire
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB PFE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback